Bitopic D3 Receptor Agonists for Selective D3R Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current D3 receptor agonists exhibit limited selectivity towards D3R over D2R, leading to cross-activation side effects and challenges in discerning their effects in in vivo studies, and existing binding studies may not accurately reflect functional selectivity.
Innovation Solution
Development of bitopic ligands derived from chemical modifications of D3 preferential agonists like PF-592,379 and (+)-PD128,907, incorporating a primary pharmacophore to bind the orthosteric binding site and a secondary pharmacophore to bind an allosteric site, enhancing D3R selectivity through specific ligand-induced receptor conformations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional D2-like receptor agonists are used, then therapeutic effects on dopaminergic system are achieved, but D3R selectivity is limited leading to cross-activation side effects
Solution Approach 1:
The ligand is divided into two distinct pharmacophores: a primary pharmacophore that binds to the orthosteric binding site and a secondary pharmacophore that binds to an allosteric site. This segmentation allows the molecule to achieve high D3R selectivity through cooperative binding, resolving the contradiction between achieving therapeutic effect and avoiding cross-activation side effects.
Solution Approach 2:
The patent creates a composite ligand structure combining two pharmacophores with different binding specificities. The primary pharmacophore provides baseline D3R affinity while the secondary pharmacophore enhances selectivity through allosteric binding, achieving >100-fold D3R over D2R selectivity and eliminating cross-activation side effects.
2Measurement precision
If radioligand competition experiments are used to assess binding selectivity, then binding affinity data is obtained, but functional selectivity may not be accurately reflected
Solution Approach 1:
The patent employs a dual-assay approach where radioligand binding data serves as initial screening, followed by functional validation assays that provide feedback on actual receptor activation. This feedback mechanism ensures that binding selectivity translates into functional selectivity, resolving the discrepancy between binding measurements and functional outcomes.
Data Source
AI summary
Disclosed herein are novel compounds including dopamine D3 receptor agonists, compositions thereof, methods of use thereof, and processes of synthesizing the same. Further disclosed are D3R selective agonist compounds, specifically bitopic ligands comprising chirality.